Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma

被引:4
|
作者
Ophuis, C. M. C. Oude [1 ]
van Akkooi, A. C. J. [2 ]
Rutkowski, P. [4 ]
Powell, W. E. M. [5 ]
Robert, C. [6 ]
Testori, A. [8 ]
van Leeuwen, B. L. [3 ]
Siegel, P. [9 ]
Eggermont, A. M. M. [7 ]
Verhoef, C. [1 ]
Grunhagen, D. J. [1 ]
机构
[1] Erasmus MC Canc Inst, Dept Surg Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands
[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Surg, Amsterdam, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Surg Oncol, Groningen, Netherlands
[4] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[5] St Georges Fdn Univ Hosp, Melanoma Unit, London, England
[6] Canc Inst Gustave Roussy, Dept Dermatol & Allergol, Villejuif, France
[7] Canc Inst Gustave Roussy, Board Directors, Villejuif, France
[8] European Inst Oncol, Div Dermatooncol Surg, Milan, Italy
[9] Charite, Dept Dermatol & Allergol, Berlin, Germany
关键词
DISSECTION; PROGNOSIS; SURVIVAL; TIME; MULTICENTER; RECURRENCE; UPDATE;
D O I
10.1002/bjs.10475
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundNodal staging with sentinel node biopsy (SNB) and completion lymph node dissection (CLND) provides prognostic information to patients with melanoma and their physicians. It is not known whether the timing of CLND is associated with survival outcome and/or CLND tumour load. This study investigated whether CLND timing is associated with CLND tumour load, disease-free survival (DFS) and/or melanoma-specific survival (MSS). MethodsA retrospective cohort of patients with SNB-positive melanoma from nine European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group centres undergoing surgery between 1993 and 2009 were examined. Patients were selected based on availability of CLND and follow-up data. The CLND interval was defined as the number of days between diagnosis and CLND. Patient and tumour characteristics were collected. Five-year DFS and MSS rates were calculated. Cox and logistic regression analysis were performed, adjusting for known prognostic/predictive indicators. ResultsA total of 784 patients were included in the study. Their median age was 51 (i.q.r. 40-62) years, and 418 patients (533 per cent) were men. Median Breslow thickness was 30 (i.q.r. 20-50)mm, and 148 patients (189 per cent) had a residual tumour load. Median CLND interval was 84 (i.q.r. 65-105) days. Five-year DFS and MSS rates were not significantly different for patients operated on with a median CLND interval of less than 84days and those with an interval of at least 84days (DFS: 542 versus 533 per cent respectively; MSS: 669 versus 651 per cent). In a multivariable Cox model, CLND interval was not a significant prognostic indicator. CLND interval was negatively correlated with identification of positive non-sentinel nodes, but following adjustment for known risk factors this effect was no longer found. ConclusionThe time interval between diagnosis of melanoma and CLND did not influence CLND tumour load, DFS or MSS. No rush
引用
收藏
页码:726 / 733
页数:8
相关论文
共 50 条
  • [21] Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma
    Lee, David Y.
    Lau, Briana J.
    Huynh, Kelly T.
    Flaherty, Devin C.
    Lee, Ji-Hey
    Stern, Stacey L.
    O'Day, Steve J.
    Foshag, Leland J.
    Faries, Mark B.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 223 (01) : 9 - 18
  • [22] Observation after a positive sentinel lymph node biopsy in patients with melanoma
    Bamboat, Zubin M.
    Coit, Daniel G.
    Konstantinidis, Ioannis
    Kuk, Deborah
    Panageas, Katherine S.
    Ariyan, Charlotte Eielson
    Brady, Mary Susan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma
    Bamboat, Zubin M.
    Konstantinidis, Ioannis T.
    Kuk, Deborah
    Ariyan, Charlotte E.
    Brady, Mary Sue
    Coit, Daniel G.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (09) : 3117 - 3123
  • [24] Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma
    Zubin M. Bamboat
    Ioannis T. Konstantinidis
    Deborah Kuk
    Charlotte E. Ariyan
    Mary Sue Brady
    Daniel G. Coit
    [J]. Annals of Surgical Oncology, 2014, 21 : 3117 - 3123
  • [25] ASO Author Reflections: Adjuvant Therapy is Effective for Melanoma Patients with Positive Sentinel Lymph Node Biopsy Who Forgo Completion Lymphadenectomy
    Norma E. Farrow
    Georgia M. Beasley
    [J]. Annals of Surgical Oncology, 2020, 27 : 5126 - 5127
  • [26] ASO Author Reflections: Adjuvant Therapy is Effective for Melanoma Patients with Positive Sentinel Lymph Node Biopsy Who Forgo Completion Lymphadenectomy
    Farrow, Norma E.
    Beasley, Georgia M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (13) : 5126 - 5127
  • [27] Melanoma Patient Quality of Life Outcomes after Sentinel Lymph Node Biopsy, Completion Lymphadenectomy, and Adjuvant Interferon
    Egger, M. E.
    Kimbrough, C.
    Stromberg, A. J.
    Quillo, A. R.
    Martin, R.
    Scoggins, C. R.
    McMasters, K. M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S24 - S24
  • [28] Is it still beneficial to have completion lymphadenectomy following positive sentinel lymph node biopsy?
    Begaj, A.
    Chu, V.
    Patel, L.
    Gajanan, K.
    [J]. BRITISH JOURNAL OF SURGERY, 2018, 105 : 26 - 26
  • [29] Completion lymph node dissection after a positive sentinel node biopsy in malignant melanoma: necessary or not? A preliminary report
    Vigato, E.
    Dalla Pozza, E.
    Bosco, F.
    Marchetti, G.
    Zannoni, M.
    Governa, M.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 65 - 65
  • [30] Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients
    Susan B. Kesmodel
    Joshua P. Kronenfeld
    Wei Zhao
    Tulay Koru-Sengul
    Neha Goel
    Daniel N. Weingrad
    Leonel Hernandez-Aya
    Jose Lutzky
    Lynn Feun
    Mary Garland-Kledzik
    Jessica S. Crystal
    [J]. Annals of Surgical Oncology, 2023, 30 : 7671 - 7685